17:36 ETThe Inner Circle acknowledges Shankari Thiagarajan as Pinnacle Professional of The Yearprnewswire·2 days ago, 04:37 PM4503ALPMY-1.54%
SMC recommends VEOZA for moderate to severe menopausal vasomotor symptomsPharmaTimes·Jul 13 at 07:07 AM4503ALPMY-1.54%
FDA approves Pfizer PADCEV-Keytruda combo for perioperative muscle-invasive bladder cancerPUBT·Jul 10 at 10:23 AMPFE+0.77%4503
Lupin Wins FDA's Tentative Approval For Enzalutamide Tablets Across Multiple Strengthsrttnews·Jun 26 at 08:59 AMALPMY-1.54%
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitorbiopharmadive·Jun 24 at 09:32 AMMKKGY+1.44%SNY-0.98%
Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circlebenzinga_article·Jun 23 at 12:46 PMSGMO0.00%ALPMY-1.54%
Sangamo Therapeutics Sets Stalking Horse Sales: $50M to Eli Lilly, Up to $50M to AstellasTradingView·Jun 23 at 07:53 AMSGMO0.00%ALPMY-1.54%
Sangamo Therapeutics files for Chapter 11 as Lilly, Astellas anchor asset sale bidsPUBT·Jun 23 at 07:05 AMSGMO0.00%LLY+1.97%
Inside Astellas CEO's plan to counter Xtandi’s patent cliffFiercepharma·Jun 11 at 05:02 PM4503ALPMY-1.54%
ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial | BAYRY Stock NewsStockTitan·May 30 at 08:25 AMBAYRY-1.57%ALPMY-1.54%
Assessing Vir Biotechnology (VIR) Valuation After Hepatitis Delta Data Update And Astellas Oncology PartnershipSimplywall·May 24 at 07:25 PMVIR-0.11%ALPMY-1.54%
Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026 | PFE Stock NewsStockTitan·May 17 at 11:00 PMALPMY-1.54%4503
